Sickle cell disease (SCD) affects more than 100,000 Americans and millions more worldwide. Vaso-occlusion, or blockage of blood vessels by blood cell aggregates, is the predominant pathophysiology in SCD. Acute systemic, painful vaso-occlusive episodes, which are the primary reasons for emergency medical care among SCD patients, is often an antecedent to acute chest syndrome (ACS), a type of acute lung injury. ACS is among the leading causes of mortality in SCD, but the current treatment for ACS is primarily supportive, and the etiological mechanism remains largely unknown.
The Sundd Lab uses a multiscale-integrative-physiologic approach involving multi-photon-excitation intravital (in vivo) microscopy of intact lung in live, transgenic, humanized SCD mice and SCD patient blood flowing through a microfluidic platform in vitro.
We have found (Bennewitz et al, JCI-Insight 2017, Bennewitz et al Blood Advances 2020, Vats et al Experimental Hematology 2020) that vaso-occlusive crisis triggered entrapment of P-selectin dependent platelet-neutrophil embolic aggregates in pulmonary arterioles, leading to the arrest of blood flow in the lung of SCD mice. Our recent work (Vats et al, AJRCCM 2020) identifies a role for platelet-inflammasome and IL-1β carrying platelet extracellular vesicles in promoting lung vaso-occlusion in SCD. Our findings suggest that inhibitors of inflammasome or IL-1β dependent innate immune pathway can be beneficial in SCD. Our more recent findings (Vats and Kaminski et al, Blood 2022) show how sterile inflammation in SCD promotes Gasdermin-D-dependent shedding of neutrophil extracellular traps (NETs) in the liver and how these NETs travel intravascularly (embolize) from the liver to the lung, to promote P-selectin-independent lung vascular vaso-occlusion in SCD.